Archive · 23 Dec 2025
Bliss GVS Pharma Appoints S.N. Kamath as MD
Bliss GVS Pharma, a company that makes medicines, has decided to make S. N. Kamath, who is already their CEO, the Managing Director too.
This decision was made by the company's board and needs to be approved by the shareholders.
If approved, Kamath will hold both positions for the next three years.
The company's stock has been doing well, going up by almost 20% in the last six months.
In the last quarter, their sales went up, but their profits went down compared to the previous quarter, but they were higher than the same time last year.
Bliss GVS Pharma's board approved S. N. Kamath as Managing Director for three years, pending shareholder approval.
Kamath is currently the CEO and promoter of the company.
The appointment is effective upon shareholder approval through a postal ballot.
The company's stock rose 1.06% on December 23, 2025, with a 19% gain over six months.
Q2 FY 2025-26 saw an 8.9% QoQ and 18.8% YoY revenue increase, but net profit declined 35.6% QoQ while rising 11.3% YoY.
- Who
- S. N. Kamath, promoter and current CEO of Bliss GVS Pharma Limited
- What
- Appointment as Managing Director for three years, subject to shareholder approval
- When
- Effective from the date of shareholder approval via postal ballot
- Where
- Bliss GVS Pharma Limited
- Why
- Board approval based on Nomination and Remuneration Committee recommendation
- Company
- Bliss GVS Pharma Limited
- Appointee
- S. N. Kamath
- Position
- Managing Director
- Tenure
- Three years (subject to shareholder approval)
- Current Role
- Chief Executive Officer
- Stock Performance
- Up 1.06% on December 23, 2025; 19% gain in six months
- Q2 FY 2025-26 Revenue Growth
- 8.9% QoQ, 18.8% YoY
- Q2 FY 2025-26 Net Profit
- Down 35.6% QoQ, up 11.3% YoY
- Earnings Per Share (Q2 FY 2025-26)
- ₹2.54